如何区分接受免疫治疗的癌症患者的假性进展与真性进展。
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.
作者信息
Ma Yiming, Wang Qiwei, Dong Qian, Zhan Lei, Zhang Jingdong
机构信息
Medical Oncology Department of Gastrointestinal Tumors, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute No. 44, Xiaohe Road, Dadong District, Shenyang 110042, Liaoning Province, China.
出版信息
Am J Cancer Res. 2019 Aug 1;9(8):1546-1553. eCollection 2019.
Abstract
Immunotherapy has achieved unprecedented clinical efficacy in patients with various types of advanced tumors; however, some patients experience delayed tumor shrinkage following an increase in tumor burden after such a therapeutic method. This phenomenon is called pseudoprogression and can lead to premature cessation of efficacious immunotherapeutic agents. Consequently, we summarized the available data on methods to differentiate pseudoprogression from true progression in patients who have been treated with immunotherapy including biomarkers, medical imaging techniques and biopsy. We also introduce hyperprogression and special pseudoprogression for improved evaluation of immunotherapy.
摘要
免疫疗法在各类晚期肿瘤患者中取得了前所未有的临床疗效；然而，一些患者在接受这种治疗方法后，肿瘤负荷增加，随后出现肿瘤延迟缩小。这种现象被称为假性进展，可能导致有效免疫治疗药物过早停用。因此，我们总结了关于在接受免疫治疗的患者中区分假性进展与真性进展的方法的现有数据，包括生物标志物、医学成像技术和活检。我们还介绍了超进展和特殊假性进展，以改进对免疫治疗的评估。
相似文献
1
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.如何区分接受免疫治疗的癌症患者的假性进展与真性进展。
Am J Cancer Res. 2019 Aug 1;9(8):1546-1553. eCollection 2019.
2
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.肺癌中的假性进展和超进展：文献综述
J Cancer Res Clin Oncol. 2020 Dec;146(12):3269-3279. doi: 10.1007/s00432-020-03360-1. Epub 2020 Aug 28.
3
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.免疫治疗后肿瘤假性进展的潜在机制、识别及临床意义
Cancer Biol Med. 2019 Nov;16(4):655-670. doi: 10.20892/j.issn.2095-3941.2019.0144.
4
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.免疫治疗的新反应形式：假性进展和超进展。
BioDrugs. 2020 Aug;34(4):463-476. doi: 10.1007/s40259-020-00425-y.
5
Pseudoprogression and hyperprogression after checkpoint blockade.免疫检查点抑制剂治疗后的假性进展和超进展。
Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23.
6
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.抗程序性细胞死亡蛋白 1 抗体治疗转移性黑色素瘤患者的循环肿瘤 DNA 与假性进展的相关性。
JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.
7
[Monitoring of immunotherapy : Possibilities and limitations].[免疫疗法的监测：可能性与局限性]
Radiologe. 2020 Aug;60(8):711-720. doi: 10.1007/s00117-020-00726-x.
8
Pseudoprogression in lung cancer patients treated with immunotherapy.免疫治疗的肺癌患者中的假性进展。
Crit Rev Oncol Hematol. 2022 Jan;169:103531. doi: 10.1016/j.critrevonc.2021.103531. Epub 2021 Nov 18.
9
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.评估免疫治疗治疗的结直肠和胰腺肿瘤的假性进展。
J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.
10
Novel patterns of response under immunotherapy.免疫治疗下的新型应答模式。
Ann Oncol. 2019 Mar 1;30(3):385-396. doi: 10.1093/annonc/mdz003.
引用本文的文献
1
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.新辅助托瑞帕利单抗联合化疗治疗局部错配修复缺陷/微卫星高度不稳定胃或食管胃交界腺癌的疗效和安全性（NICE）：一项多中心、单臂、探索性2期研究
EClinicalMedicine. 2025 Aug 12;87:103421. doi: 10.1016/j.eclinm.2025.103421. eCollection 2025 Sep.
2
Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions.癌症免疫治疗的进展与挑战：机制、临床应用及未来方向
Front Pharmacol. 2025 Jun 13;16:1602529. doi: 10.3389/fphar.2025.1602529. eCollection 2025.
3
Multiplexed imaging of radionuclides.放射性核素的多重成像。
Nat Biomed Eng. 2025 Jun 20. doi: 10.1038/s41551-025-01406-8.
4
5
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly.从十年免疫检查点抑制中吸取的经验教训：好的、坏的与丑陋的。
Cancer Metastasis Rev. 2025 Apr 4;44(2):43. doi: 10.1007/s10555-025-10260-8.
6
Cell-free DNA: plays an essential role in early diagnosis and immunotherapy of pancreatic cancer.游离DNA：在胰腺癌的早期诊断和免疫治疗中发挥着重要作用。
Front Immunol. 2025 Mar 7;16:1546332. doi: 10.3389/fimmu.2025.1546332. eCollection 2025.
7
Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature.晚期胃神经内分泌癌基于免疫疗法的治疗过程中出现多次假性进展：一例病例报告及文献综述
World J Gastrointest Oncol. 2025 Mar 15;17(3):102804. doi: 10.4251/wjgo.v17.i3.102804.
8
Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases.评估胶质母细胞瘤和脑转移瘤神经肿瘤学中的免疫治疗反应：以三例病例为特色的简要综述
Cancer Control. 2025 Jan-Dec;32:10732748251322072. doi: 10.1177/10732748251322072.
9
Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.免疫检查点抑制剂治疗开始后脑转移瘤的超进展
J Neurooncol. 2025 May;172(3):667-673. doi: 10.1007/s11060-025-04955-9. Epub 2025 Feb 7.
10
Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.使用具有独特生物相容性的金纳米棒进行靶向肿瘤内热疗，可在两种免疫原性“冷”肿瘤模型中诱导强烈的免疫原性细胞死亡。
Front Immunol. 2025 Jan 13;15:1512543. doi: 10.3389/fimmu.2024.1512543. eCollection 2024.
本文引用的文献
1
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.基于免疫检查点抑制剂治疗的晚期非小细胞肺癌中基于容积测量的超进展的全面临床和遗传特征。
J Thorac Oncol. 2019 Sep;14(9):1608-1618. doi: 10.1016/j.jtho.2019.05.033. Epub 2019 Jun 11.
2
Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment.帕博利珠单抗治疗后出现肺部空洞表现为假性进展的独特病例。
J Thorac Oncol. 2019 May;14(5):e108-e109. doi: 10.1016/j.jtho.2018.12.024.
3
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment.一名接受抗PD1治疗的mCRPC患者在PSMA PET成像上出现假性进展。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1576-1577. doi: 10.1007/s00259-019-04328-1. Epub 2019 Apr 22.
4
Atypical Response Patterns in Patients Treated With Nivolumab.接受纳武单抗治疗患者的非典型反应模式。
AJR Am J Roentgenol. 2019 Jun;212(6):1177-1181. doi: 10.2214/AJR.18.20938. Epub 2019 Mar 27.
5
Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report.肺癌患者使用纳武利尤单抗治疗期间并发心脏压塞并心包内博来霉素治疗：病例报告。
Immunotherapy. 2019 Apr;11(6):467-472. doi: 10.2217/imt-2019-0003. Epub 2019 Feb 7.
6
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.irRECIST 用于评估纳武利尤单抗治疗转移性透明细胞肾细胞癌候选生物标志物反应：一项 II 期前瞻性临床试验分析。
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.
7
Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.基于游离细胞 DNA 的全基因组测序可识别拷贝数改变，这些改变可用于监测癌症患者对免疫治疗的反应。
Mol Cancer Ther. 2019 Feb;18(2):448-458. doi: 10.1158/1535-7163.MCT-18-0535. Epub 2018 Dec 6.
8
Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.对迈克尔·施泰勒、德纳·巴特尔、阿克塞尔·贝克斯、汉斯·哈默斯和丹尼尔·乔治致编辑的信的回复，信的主题为：阿诺·梅让、阿兰·拉瓦、西蒙·泰泽纳斯等人的《舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌》。《欧洲泌尿外科杂志》2018年；74卷：842 - 843页：肾细胞癌患者接受免疫检查点抑制剂治疗时的淋巴细胞表型及根治性肾切除术时机。
Eur Urol. 2019 Mar;75(3):e64-e66. doi: 10.1016/j.eururo.2018.10.031. Epub 2018 Nov 1.
9
Hyperprogressive disease: recognizing a novel pattern to improve patient management.Hyperprogressive disease：认识一种新的模式以改善患者管理。
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2.
10
Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.氧化铁纳米颗粒 Ferumoxytol 和钆对比增强 MRI 联合定义胶质母细胞瘤假性进展。
Neuro Oncol. 2019 Mar 18;21(4):517-526. doi: 10.1093/neuonc/noy160.
Zotero 插件